The Capital Markets team advised the exclusive placement agent for Acrivon Therapeutics’ (Nasdaq: ACRV) private placement of 8,235,000 shares of its common stock, par value $0.001 per share, and pre-funded warrants to purchase up to an aggregate of 7,060,000 shares of Common Stock. The purchase price per share of Common Stock was $8.50, and the purchase price per Pre-Funded Warrant is the Purchase Price minus $0.001. The Pre-Funded Warrants will be immediately exercisable and will remain exercisable until exercised in full. The gross proceeds from the private placement were approximately $130 million, before deducting placement agent fees and other offering expenses payable by Acrivon.
Acrivon is a clinical-stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient-responder identification platform, Acrivon Predictive Precision Proteomics, or AP3.
The Goodwin team was led by Edwin O’Connor, Adam Johnson, Karin Yoo, and Li Chang and included Alexander Varond, Michael Brodowski and Olivia Uitto.
For additional details, please read Acrivon’s press release.